PUMA BIOTECHNOLOGY, INC.
No enriched coverage for $PBYI in the last 7 days.
No SEC Form 4 filings for $PBYI in the last 30 days.
See all $PBYI insider activity →Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
Recent PBYI coverage spans financial news, earnings and corporate actions.
Guidance raise and improved demand metrics for NERLYNX increase near-term earnings visibility, while royalty-rate and trade-policy risks cap upside.
Guidance raises near-term earnings visibility while amended alisertib trial dosing and enrollment timing push catalysts into Q3-Q4.
Guidance raise plus improving NERLYNX demand supports a positive near-term earnings outlook, while higher R&D spend and weaker operating cash flow add risk.
The filing is a corporate governance update; the only potentially market-relevant item is that shareholders did not approve extending the CEO’s Auerbach Warrant term.
Puma Biotechnology (PBYI) reported FY 2025 revenue and earnings exceeding expectations but faces bearish analyst forecasts for the next three years, mainly due to reliance on a single product and low valuation metrics. The stock shows signs of short-term resilience but underlying concerns may limit upside.
alphai scores every news story that mentions PBYI with an AI model for sentiment and relevance, and aggregates insider trades from PUMA BIOTECHNOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
7 min readPuma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
7 min readPUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
7 min readPUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pbyi20260613_8k.htm false 0001401667 0001401667 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report
2 min readPuma Biotechnology closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Despite improving net profit margins, analysts forecast an 11.2% annual decline in earnings over the next three years, contrasting sharply with its strong multi-year growth. The company's heavy reliance on its single product, NERLYNX, and its low P/E ratio compared to peers, reflect investor caution regarding future profitability and revenue forecasts.
5 min readIronwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
5 min readPuma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
2 min readPuma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
4 min readPuma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
3 min readHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 min read
